Lornoxicam (Synonyms: 氯诺昔康; Chlortenoxicam; Ro 13-9297)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Lornoxicam  (Synonyms: 氯诺昔康; Chlortenoxicam; Ro 13-9297) 纯度: 99.84%

Lornoxicam (Chlortenoxicam) 是高活性 COX-1 和 COX-2 抑制剂，IC50 分别为 5 nM 和 8 nM，是一个新型非甾体抗炎化合物。

Lornoxicam (Synonyms: 氯诺昔康; Chlortenoxicam; Ro 13-9297)

Lornoxicam Chemical Structure

CAS No. : 70374-39-9

规格 价格 是否有货 数量
Free Sample (0.1 – 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1228 In-stock
100 mg ￥500 In-stock
200 mg ￥800 In-stock
500 mg ￥1600 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Lornoxicam 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Pyroptosis Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library
  • Antidepressant Compound Library
  • Human Metabolite Library
  • Anti-Prostate Cancer Compound Library
  • Non-steroidal Anti-Inflammatory Compound Library
  • Off-patent Drug Library
  • Mitochondrial Toxicity Compound Library
  • Extracellular Vesicles (EVs) Compound Library
  • Multi-Target Compound Library
  • Radioprotector Library

•同靶点产品:

•同靶点蛋白产品:

生物活性

Lornoxicam (Chlortenoxicam), a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID). Target: COX Lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested. lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation ofTNF-alpha, IL-1beta and IL-8 was only moderately affected [1]. Lornoxicam is effective in the treatment of patients with activated osteoarthritis; the analgesic and anti-inflammatory effects of lornoxicam are significantly superior to those of rofecoxib without inferiority in tolerability [2]. Lornoxicam was fully effective for prevention of hyperalgesia [3].

IC50 & Target[1]

COX-1

5 nM (IC50, in cells)

COX-2

45 nM (IC50, in cells)

Clinical Trial

分子量

371.82

Formula

C13H10ClN3O4S2
CAS 号

70374-39-9
性状

固体

颜色

Light yellow to yellow

中文名称

氯诺昔康
结构分类
  • Others
初始来源
  • 内源性代谢物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
In Vitro: 

DMSO 中的溶解度 : 3.8 mg/mL (10.22 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6895 mL 13.4474 mL 26.8947 mL
5 mM 0.5379 mL 2.6895 mL 5.3789 mL
10 mM 0.2689 mL 1.3447 mL 2.6895 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

=

浓度

×

体积

×

分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×

体积 (start)

V1

=

浓度 (final)

C2

×

体积 (final)

V2

扫码获得
动物溶解方案

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果
工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.84%

Data Sheet (598 KB) SDS (419 KB)

COA (195 KB) LCMS (109 KB)

产品使用指南 (1538 KB)

参考文献

  • [1]. Spyra S, et al. COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels. Br J Pharmacol. 2017 Aug;174(16):2696-2705.  [Content Brief]

    [2]. Rose, P. and C. Steinhauser, Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig, 2004. 24(4): p. 227-36.  [Content Brief]

    [3]. Bianchi, M. and A.E. Panerai, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res, 2002. 45(2): p. 101-5.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务